Yifan Pharmaceutical Co., Ltd.
SZSE:002019.SZ
12.27 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 4,022.157 | 3,836.641 | 4,409.036 | 5,400.381 | 5,186.844 | 4,631.795 | 4,373.294 | 3,504.601 | 2,434.93 | 1,684.984 | 698.021 | 644.191 | 495.735 | 379.885 | 405.987 | 479.923 | 764.742 | 346.405 | 269.314 | 245.058 | 176.767 | 130.947 | 91.335 |
| Cost of Revenue
| 2,191.268 | 1,970.701 | 2,580.651 | 2,890.466 | 2,794.112 | 2,590.217 | 1,870.295 | 1,733.062 | 1,451.425 | 1,012.45 | 501.91 | 497.408 | 386.732 | 280.584 | 270.404 | 278.049 | 275.528 | 224.954 | 188.725 | 164.218 | 121.146 | 87.712 | 54.82 |
| Gross Profit
| 1,830.889 | 1,865.939 | 1,828.384 | 2,509.915 | 2,392.731 | 2,041.579 | 2,502.999 | 1,771.539 | 983.505 | 672.534 | 196.111 | 146.783 | 109.002 | 99.3 | 135.584 | 201.874 | 489.214 | 121.45 | 80.589 | 80.84 | 55.621 | 43.235 | 36.515 |
| Gross Profit Ratio
| 0.455 | 0.486 | 0.415 | 0.465 | 0.461 | 0.441 | 0.572 | 0.505 | 0.404 | 0.399 | 0.281 | 0.228 | 0.22 | 0.261 | 0.334 | 0.421 | 0.64 | 0.351 | 0.299 | 0.33 | 0.315 | 0.33 | 0.4 |
| Reseach & Development Expenses
| 406.946 | 190.197 | 196.639 | 325.341 | 208.493 | 167.017 | 141.228 | 105.247 | 40.66 | 20.128 | 16.192 | 18.186 | 40.241 | 26.159 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 383.692 | 131.886 | 138.847 | 173.826 | 170.666 | 102.857 | 73.725 | 73.308 | 47.777 | 39.752 | 23.522 | 21.756 | 20.236 | 27.697 | 71.547 | 86.398 | 62.239 | 39.805 | 27.416 | 29.62 | 16.301 | 12.392 | 6.242 |
| Selling & Marketing Expenses
| 1,119.148 | 1,040.992 | 892.627 | 703.369 | 628.195 | 552.508 | 437.638 | 428.023 | 368.45 | 258.707 | 34.382 | 29.051 | 25.95 | 20.34 | 20.23 | 36.585 | 43.141 | 53.791 | 13.219 | 9.577 | 6.071 | 3.563 | 3.091 |
| SG&A
| 1,498.389 | 1,172.878 | 1,031.474 | 877.194 | 798.86 | 655.364 | 511.364 | 501.33 | 416.227 | 298.459 | 57.904 | 50.807 | 46.186 | 48.037 | 91.776 | 122.983 | 105.379 | 93.596 | 40.635 | 39.197 | 22.372 | 15.955 | 9.332 |
| Other Expenses
| 841.45 | 161.892 | 248.187 | 133.059 | 190.574 | -8.274 | 23.786 | 8.743 | 71.997 | 2.649 | 2.969 | 16.591 | 1.923 | 2.836 | 6.546 | 1.017 | -1.326 | 0.466 | 0.813 | 0.807 | 3.031 | 5.181 | 0.045 |
| Operating Expenses
| 2,811.708 | 1,524.966 | 1,476.299 | 1,335.594 | 1,197.928 | 1,052.052 | 839.431 | 796.087 | 575.037 | 366.617 | 131.205 | 126.058 | 139.157 | 122.246 | 95.382 | 128.087 | 116.527 | 96.7 | 43.192 | 40.581 | 23.284 | 16.614 | 9.768 |
| Operating Income
| -882.712 | 399.375 | 348.561 | 1,084.556 | 1,076.041 | 891.123 | 1,506.444 | 899.458 | 377.199 | 299.292 | 25.344 | -3.209 | -230.121 | -186.885 | 30.055 | 55.597 | 350.258 | 7.368 | 26.152 | 39.921 | 29.5 | 24.979 | 25.671 |
| Operating Income Ratio
| -0.219 | 0.104 | 0.079 | 0.201 | 0.207 | 0.192 | 0.344 | 0.257 | 0.155 | 0.178 | 0.036 | -0.005 | -0.464 | -0.492 | 0.074 | 0.116 | 0.458 | 0.021 | 0.097 | 0.163 | 0.167 | 0.191 | 0.281 |
| Total Other Income Expenses Net
| 13.681 | 12.929 | -137.772 | -3.844 | -7.853 | -6.211 | 23.786 | -4.812 | 67.135 | 2.122 | 1.642 | 15.759 | -193.951 | -166.584 | -2.317 | -24.919 | -23.951 | -15.177 | -13.06 | -1.95 | 2.376 | 4.889 | -0.345 |
| Income Before Tax
| -869.031 | 156.737 | 210.789 | 1,080.713 | 1,068.188 | 884.912 | 1,530.23 | 894.646 | 444.334 | 301.414 | 27.057 | 11.837 | -236.174 | -194.65 | 35.241 | 48.867 | 348.736 | 6.511 | 25.651 | 39.519 | 31.876 | 29.869 | 25.326 |
| Income Before Tax Ratio
| -0.216 | 0.041 | 0.048 | 0.2 | 0.206 | 0.191 | 0.35 | 0.255 | 0.182 | 0.179 | 0.039 | 0.018 | -0.476 | -0.512 | 0.087 | 0.102 | 0.456 | 0.019 | 0.095 | 0.161 | 0.18 | 0.228 | 0.277 |
| Income Tax Expense
| 16.619 | 29.583 | -31.425 | 149.319 | 195.072 | 191.236 | 264.572 | 211.25 | 82.373 | 63.476 | 1.448 | 0.518 | 0.66 | 6.859 | 4.871 | 7.63 | 108.546 | 4.566 | 5.14 | 7.003 | 5.998 | 3.802 | 0.605 |
| Net Income
| -551.073 | 127.154 | 278.399 | 968.391 | 903.468 | 737.437 | 1,305.104 | 704.763 | 360.573 | 237.909 | 25.609 | 14.319 | -230.291 | -197.552 | 30.37 | 41.237 | 240.189 | 1.937 | 20.481 | 32.516 | 25.878 | 26.067 | 24.721 |
| Net Income Ratio
| -0.137 | 0.033 | 0.063 | 0.179 | 0.174 | 0.159 | 0.298 | 0.201 | 0.148 | 0.141 | 0.037 | 0.022 | -0.465 | -0.52 | 0.075 | 0.086 | 0.314 | 0.006 | 0.076 | 0.133 | 0.146 | 0.199 | 0.271 |
| EPS
| -0.45 | 0.11 | 0.23 | 0.8 | 0.75 | 0.61 | 1.15 | 0.64 | 0.33 | 0.35 | 0.22 | 0.026 | -0.42 | -0.36 | 0.06 | 0.088 | 0.5 | 0.02 | 0.043 | 0.047 | 0.052 | 0.053 | 0.086 |
| EPS Diluted
| -0.45 | 0.1 | 0.23 | 0.79 | 0.74 | 0.61 | 1.15 | 0.64 | 0.33 | 0.35 | 0.22 | 0.026 | -0.42 | -0.36 | 0.06 | 0.088 | 0.5 | 0.02 | 0.043 | 0.047 | 0.052 | 0.053 | 0.086 |
| EBITDA
| -483.525 | 471.013 | 492.551 | 1,342.571 | 1,306.57 | 1,068.269 | 1,704.204 | 1,036.772 | 541.866 | 327.803 | 117.618 | 96.62 | -159.384 | -135.814 | 78.555 | 106.581 | 397.937 | 54.977 | 64.4 | 64.466 | 49.769 | 31.642 | 26.972 |
| EBITDA Ratio
| -0.12 | 0.164 | 0.126 | 0.251 | 0.27 | 0.248 | 0.405 | 0.316 | 0.238 | 0.198 | 0.169 | 0.213 | 0.015 | 0.04 | 0.201 | 0.254 | 0.526 | 0.141 | 0.239 | 0.263 | 0.282 | 0.242 | 0.295 |